Evidence map›Paper›PMID 27264972›Full record

ArticleStem cell reports2016

Controlled Inhibition of the Mesenchymal Stromal Cell Pro-inflammatory Secretome via Microparticle Engineering.

Sudhir H Ranganath, Zhixiang Tong, Oren Levy, Keir Martyn, Jeffrey M Karp, Maneesha S Inamdar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Sudhir H RanganathMolecular Biology and Genetics Unit, Jawaharlal Nehru Center for Advanced Scientific Research, Jakkur, Bangalore 560064, India; Division of Biomedical Engineering, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA; Institute for Stem Cell Biology and Regenerative Medicine, GKVK - Post, Bellary Road, Bangalore 560065, India; Harvard-MIT Division of Health Sciences and Technology, 65 Landsdowne Street, Cambridge, MA 02139, USA; Department of Chemical Engineering, Siddaganga Institute of Technology, B.H. Road, Tumkur 572103, India.
Zhixiang TongDivision of Biomedical Engineering, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA; Harvard-MIT Division of Health Sciences and Technology, 65 Landsdowne Street, Cambridge, MA 02139, USA; Harvard Stem Cell Institute, 1350 Massachusetts Avenue, Cambridge, MA 02138, USA.
Oren LevyDivision of Biomedical Engineering, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA; Harvard-MIT Division of Health Sciences and Technology, 65 Landsdowne Street, Cambridge, MA 02139, USA; Harvard Stem Cell Institute, 1350 Massachusetts Avenue, Cambridge, MA 02138, USA.
Keir MartynDivision of Biomedical Engineering, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA; Harvard-MIT Division of Health Sciences and Technology, 65 Landsdowne Street, Cambridge, MA 02139, USA; Harvard Stem Cell Institute, 1350 Massachusetts Avenue, Cambridge, MA 02138, USA.
Jeffrey M KarpDivision of Biomedical Engineering, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA; Harvard-MIT Division of Health Sciences and Technology, 65 Landsdowne Street, Cambridge, MA 02139, USA; Harvard Stem Cell Institute, 1350 Massachusetts Avenue, Cambridge, MA 02138, USA. Electronic address: jeffkarp.bwh@gmail.com.
Maneesha S InamdarMolecular Biology and Genetics Unit, Jawaharlal Nehru Center for Advanced Scientific Research, Jakkur, Bangalore 560064, India; Institute for Stem Cell Biology and Regenerative Medicine, GKVK - Post, Bellary Road, Bangalore 560065, India. Electronic address: inamdar@jncasr.ac.in.
Brigham and Women's Hospital · USHarvard–MIT Division of Health Sciences and Technology · USHarvard Stem Cell Institute · USHarvard University · USJawaharlal Nehru Centre for Advanced Scientific Research · IN

Funding

Engineered Induction of a Stem Cell Homing ResponseR01HL095722 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KARP, JEFFREY MICHAEL · 2010 to 2018
$3.9M
Examining firm adhesion and transmigration of surface engineered MSCsR21HL097172 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KARP, JEFFREY MICHAEL · 2010 to 2011
$470k
NHLBI NIH HHS R01 HL095722NHLBI NIH HHS R21 HL097172
6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) are promising therapeutic candidates given their potent immunomodulatory and anti-inflammatory secretome. However, controlling the MSC secretome post-transplantation is considered a major challenge that hinders their clinical efficacy. To address this, we used a microparticle-based engineering approach to non-genetically modulate pro-inflammatory pathways in human MSCs (hMSCs) under simulated inflammatory conditions. Here we show that microparticles loaded with TPCA-1, a small-molecule NF-κB inhibitor, when delivered to hMSCs can attenuate secretion of pro-inflammatory factors for at least 6 days in vitro. Conditioned medium (CM) derived from TPCA-1-loaded hMSCs also showed reduced ability to attract human monocytes and prevented differentiation of human cardiac fibroblasts to myofibroblasts, compared with CM from untreated or TPCA-1-preconditioned hMSCs. Thus, we provide a broadly applicable bioengineering solution to facilitate intracellular sustained release of agents that modulate signaling. We propose that this approach could be harnessed to improve control over MSC secretome post-transplantation, especially to prevent adverse remodeling post-myocardial infarction.

Indexed as

Delayed-Action PreparationsDrug CarriersAmidesAnimalsBone Marrow CellsCell DifferentiationChemical EngineeringCoculture TechniquesCulture Media, ConditionedDrug CompoundingFibroblastsGene ExpressionHumansInflammationLactic AcidMesenchymal Stem Cells2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamideAmidesCulture Media, ConditionedDelayed-Action PreparationsDrug CarriersLactic AcidNF-kappa BPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerThiophenesTumor Necrosis Factor-alpha

Identifiers

PMID27264972
PMCPMC4911501
OpenAlexW2416550259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.